Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Blast Crisis 1

Interventions

Cyclophosphamide 37fludarabine phosphate 33Peripheral Blood Stem Cell Transplantation 29Methotrexate 27Busulfan 26Tacrolimus 24Cytarabine 21Antilymphocyte Serum 20Cyclosporine 19Mycophenolic Acid 18Whole-Body Irradiation 17Radiotherapy 15Methylprednisolone 15Filgrastim 13merphos 10Melphalan 10Cord Blood Stem Cell Transplantation 10Imatinib Mesylate 9Etoposide 9Granulocyte Colony-Stimulating Factor 7Thiotepa 6Rituximab 6sargramostim 5fludarabine 5Vincristine 5Sirolimus 5Prednisone 5Idarubicin 5Cladribine 5thymoglobulin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Blast Crisis × troxacitabine × Clear all
NCT00012259 2021-06-10

Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia

Takeda

Phase 2 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡